Hyperfine (HYPR) AI Stock Analysis

• Market Cap: $57.57M
• Dividend Yield: N/A
• Average Volume (3M): 4.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: 0.34%
• EPS Growth: 6.20%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 62,784,560
• 10 Day Avg. Volume: 11,371,717
• 30 Day Avg. Volume: 4,002,953
• PEG Ratio: -0.76
• Price to Book (P/B): 1.11
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.48
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 0.41
• Enterprise Value/Gross Profit: 3.49
• Enterprise Value/Ebitda: -0.12
• 1Y Price Target: $1.10
• Price Target Upside: 48.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $1.00 ▲(35.14%Upside)

Hyperfine's overall score is influenced by its strong revenue growth and solid equity position, but is constrained by persistent profitability challenges. Technical indicators show mixed signals with short-term momentum, while valuation metrics highlight ongoing losses. Strategic initiatives from the earnings call offer growth potential, but cautious sentiment is warranted due to existing operational challenges.

Positive Factors

Product Expansion

The sales pipeline is solid, with two new indications (Alzheimer’s, Stroke) set to expand the total addressable market from $1.5 billion to over $6 billion.

Strategic Partnerships

HYPR is partnering with NVIDIA to develop future technologies that incorporate NVIDIA's advanced artificial intelligence (AI) capabilities with the Swoop system.

Negative Factors

Revenue Performance

Revenue of $2.1M missed both consensus and our estimate ($2.8M) by ~$0.7M.

Selling Cycle Challenges

HYPR is seeing an elongation in their selling cycle of up to ~18 months due to ongoing softness in the hospital capital environment.

Hyperfine Business Overview & Revenue Model

Company Description

Hyperfine (HYPR) is a pioneering medical technology company dedicated to transforming healthcare through its development of portable, affordable, and easy-to-use MRI systems. Operating within the medical imaging sector, Hyperfine's flagship product, the Swoop Portable MR Imaging System, is designed to provide real-time brain imaging at the point of care, enhancing diagnostic capabilities in diverse clinical settings including emergency departments, intensive care units, and rural or underserved areas.

How the Company Makes Money

Hyperfine makes money through the sale and leasing of its Swoop Portable MR Imaging System. The company's revenue model includes direct sales to hospitals and healthcare facilities, as well as leasing arrangements that provide a recurring revenue stream. Additionally, Hyperfine generates income from ongoing service and maintenance contracts, ensuring optimal performance and longevity of their imaging systems. Strategic partnerships with healthcare providers and collaborations with research institutions also contribute to its revenue, expanding its market reach and fostering innovation in portable medical imaging solutions.

Hyperfine Financial Statement Overview

Summary

While Hyperfine shows strong revenue growth and a solid equity position without debt, it continues to face profitability challenges with substantial net losses and negative cash flows. The high equity ratio is a strength, but ongoing operational inefficiencies and a negative ROE are major concerns.

Income Statement

Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.

Balance Sheet

The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.

Cash Flow

Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
12.89M	11.03M	6.81M	1.50M	294.00K
	Gross Profit
5.89M	4.76M	907.00K	-1.17M	-477.00K
	EBIT
-43.22M	-48.12M	-73.87M	-64.87M	-23.49M
	EBITDA
-42.22M	-47.06M	-72.86M	-64.14M	-23.20M
	Net Income Common Stockholders
-40.72M	-44.24M	-72.45M	-64.83M	-23.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.65M	75.18M	117.47M	188.50M	62.68M
	Total Assets
58.90M	94.20M	134.05M	202.47M	71.53M
	Total Debt
269.00K	185.00K	0.00	0.00	178.00K
	Net Debt
-37.38M	-75.00M	-117.47M	-188.50M	-62.50M
	Total Liabilities
9.86M	9.80M	10.33M	16.25M	132.58M
	Stockholders Equity
49.04M	84.40M	123.72M	186.23M	-61.05M
Cash Flow		Free Cash Flow
-39.15M	-42.61M	-72.92M	-49.89M	-23.09M
	Operating Cash Flow
-38.77M	-41.81M	-72.34M	-47.18M	-21.52M
	Investing Cash Flow
-383.00K	-804.00K	-585.00K	-2.71M	-1.57M
	Financing Cash Flow
1.02M	174.00K	7.00K	176.77M	60.94M

Hyperfine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.74
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 0.74 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.69, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.57 is Neutral, neither overbought nor oversold. The STOCH value of 35.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICAD	60 Neutral	$107.14M	―	-16.53%	―	-4.15%	3.49%
TELA	57 Neutral	$62.10M	―	-267.29%	―	12.78%	15.53%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
HYPR	52 Neutral	$57.57M	―	-67.86%	―	0.34%	6.20%
MRSN	47 Neutral	$43.47M	―	-505.14%	―	-11.21%	47.20%
KZR	42 Neutral	$32.07M	―	-57.78%	―	-100.00%	18.17%
RBOT	39 Underperform	$44.67M	―	-104.36%	―	―	-1455.58%

Hyperfine Corporate Events

Hyperfine Chairperson R. Scott Huennekens Resigns

On May 21, 2025, R. Scott Huennekens, Chairperson of Hyperfine, Inc.’s Board of Directors, announced his resignation effective May 22, 2025, due to personal reasons and other commitments. His departure was not due to any disagreements with the company. The Board expressed gratitude for his service since 2021 and, in response, reduced its size from six to five members. Daniel J. Wolterman, a current board member, was appointed as the new Chairperson, and the company anticipates his leadership.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Holds Annual Stockholders Meeting

On May 19, 2025, Hyperfine, Inc. held its annual meeting of stockholders, where approximately 90.95% of the voting power was represented. During the meeting, all board nominees were reelected, and Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (HYPR) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.